

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/832,174	04/10/2001	Darryl Desmarteau	CXU-328	8803		
75	590 09/30/2003					
John E. Vick, Jr. Dority & Manning, Attorneys at Law, P.A.			EXAMINER			
			O SULLIVAN, PETER G			
P.O. Box 1449	20602			•		
Greenville, SC 29602			ART UNIT	PAPER NUMBER		
			1621			
			DATE MAILED: 09/30/2003			

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. 09/832,174

Applicant(s)

Examiner

Art Unit

Desmarteau et al.



## Office Action Summary

		Peter O	Sullivan		1621	
	The MAILING DATE of this communication appears	on the cover she	eet with the	e corres	pondence address	
	for Reply					
THE N - Extens mailing - If the p	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION. ions of time may be available under the provisions of 37 CFR 1.136 (a). In a date of this communication. Deriod for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply the specified above.	no event, however, m	ay a reply be ti	imely filed ays will be	after SIX (6) MONTHS to	
- Failure - Any re	to reply within the set or extended period for reply will, by statute, cause to ply received by the Office later than three months after the mailing date of patent term adjustment. See 37 CFR 1.704(b).	he application to becom	ne ABANDONE	D (35 U.S	.C. § 133).	
Status						
1) 💢	Responsive to communication(s) filed on <u>Dec 2, 20</u>	002				<u> </u>
2a) 🗌	This action is <b>FINAL</b> . 2b) 🗓 This action	tion is non-final.				
3) 🗆	Since this application is in condition for allowance closed in accordance with the practice under Ex pa	*				nerits is
Disposi	tion of Claims					
4) 💢	Claim(s) <u>1-21</u>			_ is/are	pending in the a	pplication.
4	a) Of the above, claim(s) 21			_ is/are	e withdrawn fron	n consideration.
5) 🗆	Claim(s)				is/are allowed.	
6) 💢	Claim(s) <u>1-20</u>				is/are rejected.	
7) 🗆	Claim(s)				is/are objected to	).
8) 🗌	Claims	are	subject to	restric	tion and/or elect	on requirement.
Applica	tion Papers					
9) 🗆	The specification is objected to by the Examiner.					
10)□	The drawing(s) filed on is/are	e a) 🗆 accepted	d or b) 🗆 (	objecte	d to by the Exan	iner.
	Applicant may not request that any objection to the o	_				
11)∐	The proposed drawing correction filed on  If approved, corrected drawings are required in reply			roved	b)□ disapproved	l by the Examiner.
12)	The oath or declaration is objected to by the Exam					
Priority	under 35 U.S.C. §§ 119 and 120					
13) 🗌	Acknowledgement is made of a claim for foreign $\boldsymbol{\rho}$	riority under 35	U.S.C. §	119(a)	·(d) or (f).	
a) 🗆	☐ All b)☐ Some* c)☐ None of:					
	1. $\square$ Certified copies of the priority documents hav	ve been received	d.			
	2. $\square$ Certified copies of the priority documents have	re been received	in Applic	ation N	o	·
	<ol> <li>Copies of the certified copies of the priority d application from the International Bure se the attached detailed Office action for a list of th</li> </ol>	au (PCT Rule 1	7.2(a)).		this National Sta	ge
. —	Acknowledgement is made of a claim for domestic				۵۱	
_	The translation of the foreign language provisions				o,.	
_	Acknowledgement is made of a claim for domestic				and/or 121.	
Attachm		•	- 1			
1) 🙀 No	tice of References Cited (PTO-892)	4) Interview Sun	nmary (PTO-41	3) Paper N	lo(s).	
2) No	tice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Info	rmal Petent Ap	plication (	PTO-152)	
3) 💢 Inf	ormation Disclosure Statement(s) (PTO-1449) Paper No(s)4	6) Other:				

Application/Control Number: 09/832,174 Page 2

Art Unit: 1621

- 1. Claims 1-21 are pending in this application which should be reviewed for errors. In response to the restriction requirement, applicants elected with traverse group I, claims 1-20. In response to the further requirement for the election of a single disclosed species, applicants elected the iodonium salt where R1 and R2 are alkyls and X is of the scope of claim 4. Applicants' compounds wherein X comprises a sulfonylaminosulfonyl moiety and which are not cyano or ester substituted are examined therewith with all other compounds and claim 21 held withdrawn from consideration.
- 2. The following is a quotation of the first paragraph of 35 U.S.C. 112:
  - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 3. Claim 1 is rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for compounds limited to the scope of claim 2, does not reasonably provide enablement for applicants' comopunds substituted by all sulfur, nitrogen or fluorine containing groups. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims. Applicants' compounds as claimed could include, for example, perthiocarbonate groups not given adequate enablement in the specification.
- 4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Application/Control Number: 09/832,174 Page 3

Art Unit: 1621

5. Claims 1- 6 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. "Alkoxys" appears to be a misspelling in line 6 and at any rate redundant in view of line 4.

- 6. Claims 15 and 16 are objected to as duplicate claims.
- 7. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

8. Claims 1-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Michot et al., US 6,319,428 who disclose iodonium inner salts for use in ionic conducting materials. Michot et al. discloses compound of the formula disclosed in line 17 of column 2, but later in column 4, lines 17-19 discloses the anion and cation may be together in a zwitterion. The anticipating compound

Application/Control Number: 09/832,174 Page 4

Art Unit: 1621

(4-butoxybenzene)-[trifluoromethanesulfonyl-(4-phenylsulfonyl)imide]iodonium is disclosed in example 51, col. 51, top). The instant invention differs from the teaching of Michot et al. in that although generically disclosed, not all of applicants' compounds are exemplified. It would have been <u>prima facie</u> obvious at the time the invention was made to one of ordinary skill in the art to start with the teaching Michot et al., to make further generically disclosed compounds especially in view of the anticipating example, and to expect to produce compounds having utility in ionic conducting materials.

9. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) do not apply to the examination of this application as the application being examined was not (1) filed on or after November 29, 2000, or (2) voluntarily published under 35 U.S.C. 122(b). Therefore, this application is examined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

10. Claims 1-5 rejected under 35 U.S.C. 102(e) as being anticipated by Michot et al. who disclose the anticipating compound noted above.

Application/Control Number: 09/832,174

Art Unit: 1621

11. No claim is allowed.

12. Any inquiry concerning this communication should be directed to Peter O'Sullivan at telephone number 703 (308)-4526.

PETER O'SULLIVAN PRIMARY EXAMINER GROUP 1200

Page 5